Correlation between neutrophil-to-lymphocyte ratio and severity of myasthenia gravis in adults: A retrospective study


      • Compare the difference of clinical data between mild MG, severe MG, and HC.
      • NLR > 2.37 can differentiate severe MG from mild MG.
      • NLR may be a helpful marker to evaluate the severity disease of patients with MG especially mild MG.



      The study aimed to explore the clinical value of neutrophil-to-lymphocyte (NLR) in evaluating myasthenia gravis (MG) severity and the correlation between NLR and the Quantitative Myasthenia Gravis Score (QMGS).


      This study included 128 patients with MG and 116 healthy controls. We completed Myasthenia Gravis Foundation of America (MGFA) classification for patients with MG, and defined MGFA I, II, and III as mild MG and MGFA IV and V as severe MG. The NLR of the patients were calculated, and statistical analysis was performed, with statistical significance set at P < 0.05. When pairwise comparisons between patients with mild MG, severe MG, and the healthy controls were performed, P < 0.017 was considered statistically significant under Bonferroni correction.


      NLR was significantly higher in patients with severe MG than in those with mild MG [2.90(2.41–5.83) vs 1.72(1.38–2.51), P = 0.000] and in the healthy controls [2.90(2.41–5.83) vs 1.65(1.34–1.91), P = 0.000]. NLR was independently associated with severe MG. The cut-off value of NLR for differentiating mild MG from severe MG was 2.37, and the sensitivity and specificity were 0.900 and 0.815, respectively. The results of Spearman test showed that NLR was positively correlated with QMGS in mild MG. NLR tended to be correlated QMGS in patients with severe MG, but the difference was not statistically significant.


      NLR may be a helpful marker for identifying patients with severe MG. NLR can also be used to further evaluate disease severity, especially for mild MG.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Clinical Neuroscience
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Koneczny I.
        • Herbst R.
        Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture.
        Cell. 2019; 8: 671
        • Hehir M.K.
        • Silvestri N.J.
        Generalized Myasthenia Gravis: Classification, Clinical Presentation, Natural History, and Epidemiology.
        Neurol Clin. 2018; 36: 253-260
        • Jaretzki A.
        • Barohn R.J.
        • Ernstoff R.M.
        • Kaminski H.J.
        • Keesey J.C.
        • Penn A.S.
        • et al.
        Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America.
        Neurology. 2000; 55: 16-23
        • Yu S.
        • Lin J.
        • Fu X.
        • Li J.
        • Li Y.
        • Chen B.
        • et al.
        Risk factors of myasthenic crisis after thymectomy in 178 generalized myasthenia gravis patients in a five-year follow-up study.
        Int J Neurosci. 2014; 124: 792-798
        • Ekici H.
        • Imamoglu M.
        • Okmen F.
        • Gencosman G.
        • Ak G.
        • Ergenoglu M.
        Evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in pregnant women with systemic lupus erythematosus.
        J Obstet Gynaecol. 2021; 25: 1-5
        • Benvenuti E.
        • Pierini A.
        • Gori E.
        • Lucarelli C.
        • Lubas G.
        • Marchetti V.
        Neutrophil-to-Lymphocyte Ratio (NLR) in Canine Inflammatory Bowel Disease (IBD).
        Vet Sci. 2020; 7: 141
        • Hemond C.C.
        • Glanz B.I.
        • Bakshi R.
        • Chitnis T.
        • Healy B.C.
        The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis.
        BMC Neurol. 2019; 19: 23
        • Lin J.
        • Xue B.
        • Li J.
        • Xu H.
        • Huang X.
        • Yao Z.
        • et al.
        Neutrophil to lymphocyte ratio may be a helpful marker to evaluate disease activity in NMOSD.
        Neurol Sci. 2017; 38: 1859-1863
        • Jiang Z.
        • Ning Z.
        • Yang L.
        • Chen B.
        • Tang J.
        • Zhang J.
        • et al.
        The correlation of neutrophil-to-lymphocyte ratio with the presence and short-time curative effect of myashtenia gravis in children: a retrospective study.
        Int J Neurosci. 2021; 131: 894-901
        • Yang D.
        • Qian M.
        • Wei M.
        • Li J.
        • Yu M.
        • Lu X.
        • et al.
        The correlation of neurtrophil-to-lymphocyte ratio with the presence and activity of myasthenia gravis.
        Oncotraget. 2017; 8: 76099-76107
        • Ghafouri-Fard S.
        • Azimi T.
        • Hussen B.M.
        • Taheri M.
        • Jalili K.R.
        A Review on the Role of Non-Coding RNAs in the Pathogenesis of Myasthenia Gravis.
        Int J Mol Sci. 2021; 22: 12964
        • Wang Z.
        • Yan Y.
        Immunopathogenesis in myasthenia gravis and neuromyelitis optica.
        Front Immunol. 2017; 8: 1785
        • Cavalcante P.
        • Barzago C.
        • Baggi F.
        • Antozzi C.
        • Maggi L.
        • Mantegazza R.
        • et al.
        Toll-like receptors 7 and 9 in myasthenia gravis thymus: amplifiers of autoimmunity?.
        Ann N Y Acad Sci. 2018; 1413: 11-24
        • Uzawa A.
        • Kuwabara S.
        • Suzuki S.
        • Imai T.
        • Murai H.
        • Ozawa Y.
        • et al.
        Roles of cytokines and T cells in the pathogenesis of myasthenia.
        Clin Exp Immunol. 2021; 203: 366-374
        • Zhang C.-J.
        • Gong Y.e.
        • Zhu W.
        • Qi Y.
        • Yang C.-S.
        • Fu Y.
        • et al.
        Augmentation of Circulating Follicular Helper T Cells and Their Impact on Autoreactive B Cells in Myasthenia Gravis.
        J Immunol. 2016; 197: 2610-2617
        • Kurata I.
        • Matsumoto I.
        • Sumida T.
        T follicular helper cell subsets: a potential key player in autoimmunity.
        Immunol Med. 2021; 44: 1-9
        • Howard Jr., J.F.
        Myasthenia gravis: the role of complement at the neuromuscular junction.
        Ann N Y Acad Sci. 2018; 1412: 113-128
        • Çebi M.
        • Durmus H.
        • Aysal F.
        • Özkan B.
        • Gül G.E.
        • Çakar A.
        • et al.
        CD4+T cells of myasthenia gravis patients are characterized by increased IL-21, IL-4 and IL-17A productions and higher presence of PD-1 and ICOS.
        Front Immunol. 2020; 11
        • Cao Y.
        • Amezquita R.A.
        • Kleinstein S.H.
        • Stathopoulos P.
        • Nowak R.J.
        • O'Connor K.C.
        • et al.
        Autoreactive T cells from patients with myasthenia gravis are characterized by elevated IL-17, IFN-γ and GM-CSF and diminished IL-10 production.
        J Immunol. 2016; 196: 2075-2084
      1. Hou MM, Li YF, He LL, Li XQ, Zhang Y, Zhang SX., et al. Proportions of Th17 cells and Th17-related cytokines in neuromyelitis optica spectrum disorders patients: A meta-analysis. Int Immunopharmacol. 2019; 75: 105793.

        • Berrih-Aknin S.
        Myashenia gravis: paradox versus paradigm in autoimmunity.
        J Autoimmun. 2014; 52: 1-28
        • Zhou Y.
        • Xie H.
        • Zhang J.
        • Zhang J.
        • Li Y.
        • Duan R.
        • et al.
        Neutrophil-to-lymphocyte ratio on admission is an independent risk factor for the severity of neurological impairment at disease onset in patients with a first episode of neuromyelitis optica spectrum disorder.
        Neuropsychiatr Dis Treat. 2021; 17: 1493-1503
        • De Bondt M.
        • Hellings N.
        • Opdenakker G.
        • Struyf S.
        Neutrophils: Underestimated Players in the Pathogenesis of Multiple Sclerosis (MS).
        Int J Mol Sci. 2020; 21: 4558
        • Rodríguez M.S.
        • Farez M.F.
        • et al.
        The Immune Response in Multiple Sclerosis.
        Annu Rev Pathol. 2022 17,; : 121-139
        • Hou M.M.
        • Li Y.F.
        • He L.L.
        • et al.
        Proportions of Th17 cells and Th17-related cytokines in neuromyelitis optica spectrum disorders patients: A meta-analysis.
        Int Immunopharmacol. 2019; 75105793
        • Duan Z.
        • Feng J.
        Comparison of neutrophil-to-lymphocyte ratio between myelin oligodendrocyte glycoprotein antibody-associated disease and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders in adults.
        J Clin Neurosci. 2022; 101: 89-93
        • Bisgaard A.K.
        • Pihl-Jensen G.
        • Frederiksen J.L.
        The neutrophil-to-lymphocyte ratio as disease actvity marker in multiple sclerosis and optic neuritis.
        Mult Scler Relat Disord. 2017; 18: 213-217
        • Xie H.
        • Zhao Y.
        • Pan C.
        • Zhang J.
        • Zhou Y.
        • Li Y.
        • et al.
        Association of neutrophil-to-lymphocyte ratio (NLR) with the prognosis of first attack neuromyelitis optica spectrum diorder (NMOSD): a retrospective cohort study.
        BMC Neurol. 2021; 21: 389
        • Gelibter S.
        • Pisa M.
        • Croese T.
        • Costa G.D.
        • Orrico M.
        • Preziosa P.
        • et al.
        Neutrophil-to-lymphocyte ratio: a marker of neuroinflammation in multiple sclerosis?.
        J Neurol. 2021; 268: 717-723
        • Carnero Contentti E.
        • Delgado-García G.
        • Criniti J.
        • López P.A.
        • Pettinicchi J.P.
        • Cristiano E.
        • et al.
        An abnormally high neutrophil-to-lymphocyte ratio is not an independent outcome predictor in AQP4-IgG-Positive NMOSD.
        Front Immunol. 2021; 12628024